(MSLC) Morgan Stanley Pathway - NYSE

ETF Category: Large Blend | Exchange: NYSE (USA) | Market Cap: 3.943m USD | Total Return: 21.9% in 12m

Large Cap Stocks, Equity Securities, Exchange Traded Funds
Total Rating 45
Safety 40
Buy Signal -0.42
Large Blend
Category Rotation: -9.4
AUM: 3.94B
Avg Turnover: 4.24M
Risk 3d forecast
Volatility17.3%
VaR 5th Pctl3.23%
VaR vs Median3.97%
Reward TTM
Sharpe Ratio1.33
Rel. Str. IBD52.2
Rel. Str. Peer Group22
Character TTM
Beta0.946
Beta Downside0.957
Hurst Exponent0.518
Drawdowns 3y
Max DD17.86%
CAGR/Max DD0.75
CAGR/Mean DD5.47

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: MSLC Morgan Stanley Pathway

The Morgan Stanley Pathway Large Cap Equity ETF (MSLC) focuses on long-term capital appreciation by investing at least 80% of its assets in large-capitalization equity securities. The fund utilizes the Russell 1000 Index as its primary benchmark for defining the market capitalization range of its holdings. As a Large Blend ETF, it typically balances exposure between growth and value stocks to mitigate sector-specific volatility.

Large-cap companies generally offer greater financial stability and more consistent dividend payments compared to small-cap firms due to their established market positions. This investment model prioritizes liquidity and lower relative risk, making it a common core component for institutional and retail portfolios. Investors can find deeper insights into these equity fundamentals by exploring the data on ValueRay.

Headlines to Watch Out For
  • Broad market performance of Russell 1000 constituents drives net asset value
  • Federal Reserve monetary policy shifts impact large-cap equity valuations and multiples
  • Institutional inflows to Morgan Stanley wealth platforms increase fund assets under management
  • Relative performance against S&P 500 benchmarks influences competitive capital allocation
What is the price of MSLC shares?

As of June 20, 2026, the stock is trading at USD 58.74 with a total of 61,163 shares traded.
Over the past week, the price has changed by +1.28%, over one month by +1.28%, over three months by +11.97% and over the past year by +21.87%.

Is MSLC a buy, sell or hold?

Morgan Stanley Pathway has no consensus analysts rating.